PCSK9 inhibitor evolocumab not associated with decline in memory or cognitive function

March 19, 2017

New trial results show that in patients on statin therapy, the addition of evolocumab did not result in a significant change in cognitive function after 19 months of treatment.

A new class of cholesterol lowering drugs, PCSK9 inhibitors, effectively lower LDL cholesterol levels beyond current treatment targets, and new research shows that these lower levels result in a reduction in , making these drugs attractive treatment options for who do not achieve their target cholesterol level with alone. However, previous research had raised the possibility that a low level of LDL cholesterol and/or use of statins may negatively impact memory and overall cognition. New research led by the TIMI Study Group at Brigham and Women's Hospital in collaboration with Brown University and the University of Geneva reassuringly finds no association between the use of the PCSK9 inhibitor evolocumab and a decline in memory or cognitive function.

The findings were presented at the American College of Cardiology Scientific Sessions on March 18, 2017. Full results of the study are expected to be published in a peer-reviewed journal in the coming months.

"After an average of 19 months of treatment, our data show that changes in memory and cognitive function were very small and similar between patients treated with evolocumab and those treated with placebo," said Robert Giugliano, MD, SM, a senior investigator in the TIMI Study Group and physician in the Cardiovascular Division at BWH. "These data should reassure physicians and patients who may have had questions about the safety of this drug as it pertains to cognitive impairment."

Using a computer tablet-based tool, researchers assessed the executive function, working memory, episodic memory and psychomotor speed of 1,974 patients who were enrolled in EBBINGHAUS, a substudy embedded in the FOURIER trial. FOURIER was designed to evaluate the impact of evolocumab on cardiovascular outcomes in patients on statin therapy, and found that evolocumab significantly reduced cardiovascular events, with a larger effect the longer patients were treated.

For EBBINGHAUS, patients performed baseline cognitive tests at the time of enrollment, and at six, 12 and 24 months. In the primary analysis, researchers compared changes in the baseline measurement in 1,204 patients who had a cognitive assessment on or prior to the first day they received evolocumab or placebo; a secondary analysis compared results in all 1,974 patients, including 770 patients who had baseline testing after the first dose but no later than the week 12 visit.

"We examined tests of potential adverse effects of the treatment on not only memory but also attention and reaction time that are important aspects of cognition that could seriously impact daily functioning," said Brian R. Ott, MD a physician in the Department of Neurology at Rhode Island Hospital and the Alpert Medical School of Brown University, and member of the EBBINGHAUS study steering committee. "We found no significant differences during the course of the study between the active and placebo treatment groups for any of these cognitive domains.

Results of cognitive testing also did not vary by the achieved level of low-density (bad) cholesterol, including the group who were treated with evolocumab and achieved low-density cholesterol below 25 mg/dL, a level that is far below current treatment goals.

In addition to collecting data from the computer tablet-based test, researchers also collected and analyzed information from self-reported patient assessments of everyday function, and investigator-reported adverse events related to memory and cognition. For both of these measures, there were no significant differences between the and the placebo groups.

Explore further: Study suggests new drug alongside statins can significantly cut cholesterol

Related Stories

Study suggests new drug alongside statins can significantly cut cholesterol

March 17, 2017
A new class of cholesterol-lowering drug has been found to help patients cut their risk of cardiovascular disease, stroke and heart attack.

Evolocumab significantly reduces risk of cardiovascular events

March 17, 2017
Evolocumab, one of the new targeted PCSK9 inhibitor drugs that has been shown to dramatically lower levels of low-density lipoprotein (LDL), or "bad" cholesterol, also significantly lowers the risk of cardiovascular events ...

Evolocumab safely drops LDL cholesterol well below statin-only baseline

March 31, 2014
The monoclonal antibody evolocumab produced highly significant reductions in low-density lipoprotein (LDL) cholesterol, the "bad cholesterol," as an add-on to statins in all treatment groups, according to data from the LAPLACE-2 ...

AHA: Evolocumab can help substantially reduce LDL

November 16, 2016
(HealthDay)—Combining statins with the PCSK9 inhibitor evolocumab can help reduce low-density lipoprotein (LDL) cholesterol to previously unseen levels, according to a study published online Nov. 15 in the Journal of the ...

Cholesterol lowering therapies for patients with muscle-related statin intolerance

April 3, 2016
Steven E. Nissen, M.D., of the Cleveland Clinic, and colleagues identified patients with muscle-related adverse effects from statins and compared lipid-lowering efficacy for two nonstatin therapies, ezetimibe and evolocumab. ...

Statin intolerance objectively identified in patients

April 3, 2016
In the first major trial of its kind, Cleveland Clinic researchers used a blinded rechallenge with atorvastatin or placebo to objectively confirm the presence of muscle-related symptoms in patients with a history of intolerance ...

Recommended for you

Early study shows shoe attachment can help stroke patients improve their gait

December 14, 2017
A new device created at the University of South Florida – and including a cross-disciplinary team of experts from USF engineering, physical therapy and neurology – is showing early promise for helping correct the signature ...

Scientists rewrite our understanding of how arteries mend

December 13, 2017
Scientists from The University of Manchester have discovered how the severity of trauma to arterial blood vessels governs how the body repairs itself.

Deadly heart rhythm halted by noninvasive radiation therapy

December 13, 2017
Radiation therapy often is used to treat cancer patients. Now, doctors at Washington University School of Medicine in St. Louis have shown that radiation therapy—aimed directly at the heart—can be used to treat patients ...

Ultra-thin tissue samples could help to understand and treat heart disease

December 12, 2017
A new method for preparing ultra-thin slices of heart tissue in the lab could help scientists to study how cells behave inside a beating heart.

Young diabetics could have seven times higher risk for sudden cardiac death

December 12, 2017
Young diabetics could have seven times more risk of dying from sudden cardiac arrest than their peers who don't have diabetes, according to new research.

Research reveals how diabetes in pregnancy affects baby's heart

December 12, 2017
Researchers at the Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research at UCLA have discovered how high glucose levels—whether caused by diabetes or other factors—keep heart cells from maturing ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.